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In this issue, we publish an unusual Meeting Report (p 437). It
looks back over 20 years of drug development inspired by the late
Tom Connors and brought to fruition through the work of the
Phase I/II Clinical Trials Committee of Cancer Research UK
(formerly of the Cancer Research Campaign). In celebrating
impressive achievements and current strengths, the speakers also
look forward to further progress and development ranging from
small molecular weight antagonists of cell proliferation and
endocrine stimulation to antibody-targeted treatment and gene
therapy based on the metabolic activation of prodrugs.
What is remarkable is that this Clinical Trials Committee in the
UK has selected some 89 agents for 85 Phase I trials, and 30 have
progressed to further clinical investigation. The Committee had a
small budget but large ambitions. It has won great respect not only
in the British community of clinical researchers, but also at the US
National Cancer Institute and from the European Organisation for
Research and Treatment of Cancer (EORTC). Tom Connors, a
trusted collaborator and facilitator, tirelessly built up a network of
formal and informal links that led to many international successes.
Drugs such as temozolomide, 4-hydroxyandrostenedione and
carboplatin were first tested in patients under the auspices of the
Phase I/II Clinical Trials Committee.
Phase I and II clinical trials, carefully supervised and conducted
to the highest standards, are crucial before investing in Phase III
randomised control trials involving large numbers of patients and
considerable costs. For every success in this field, there are many
near misses and failures, so it is also important both to patients
and the pharmaceutical industry to know when to abandon a drug
that initially appeared promising. The Phase I/II Clinical Trials
Committee has never shied away from harsh decisions over its
members’ favourite therapeutic. It has insisted on the highest
standards in accordance with the requirements of international
regulatory agencies when evaluating potential therapies, whilst at
the same time supporting the development of novel means of
measuring the efficacy, pharmacokinetics and pharmacodynamics
of the drugs in action.
As the Meeting Report concludes, by any standards the
achievements of the Phase I/II Committee have made an
impressive contribution to international anticancer drug discovery
and evaluation, to the benefit of cancer patients. That is due in no
small part to the vision, enthusiasm and rigour of its founders.
Those who now constitute the Committee are well placed to
continue its role in introducing future drugs based on rational
design tailored to targets revealed by our growing understanding
of the molecular pathways that become aberrant in cancer cells.
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